Ascentage Pharma Overview

  • Founded
  • 2009
  • Status
  • Public
  • Employees
  • 531
  • Stock Symbol
  • 06855
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $3.97
  • (As of Wednesday Closing)

Ascentage Pharma General Information


Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Stock Exchange
Primary Office
  • 218 Xinghu Street Building B7
  • 7th Floor, Suzhou Industrial Park
  • Suzhou, Jiangsu 215000
  • China
+86 0512 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ascentage Pharma Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.97 $4.17 $3.35 - $7.49 $1.1B 264M 973K -$0.47

Ascentage Pharma Financials Summary

In Thousands,
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 1,457,329 1,078,557 1,059,081
Revenue 3,439 1,802 2,100 1,029
EBITDA (106,708) (93,650) (211,952) (45,136)
Net Income (110,875) (98,081) (214,297) (52,198)
Total Assets 372,493 264,956 172,229 178,714
Total Debt 103,232 81,076 14,493 6,112
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ascentage Pharma Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ascentage Pharma‘s full profile, request access.

Request a free trial

Ascentage Pharma Patents

Ascentage Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210230174-A1 Spirocyclic tetrahydroquinazolines Pending 08-Jan-2020 0000000000
US-20210186939-A1 Mdm2 inhibitor and a platinum compound for cancer treatment Pending 19-Dec-2019 0000000000
EP-3861990-A1 Pharmaceutical composition of alkynyl-containing compound, preparation method therefor and application thereof Pending 09-Dec-2019 0000000000
AU-2019449883-A1 Pharmaceutical composition containing alkynyl compound and preparation method and application thereof Pending 09-Dec-2019 0000000000
EP-3843751-A1 Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases Pending 31-Jul-2019 A61K45/06

Ascentage Pharma Executive Team (8)

Name Title Board Seat Contact Info
Dajun Yang Ph.D Chief Executive Officer & Chairman
Ming Guo Ph.D Co-Founder, President & Chief Operating Officer
Yiqing Chen Chief Financial Officer
Jeff Kmetz Chief Business Officer
Gang Zhu Chief Commercial Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Ascentage Pharma Board Members (9)

Name Representing Role Since
Dajun Yang Ph.D Ascentage Pharma Chief Executive Officer & Chairman 000 0000
David Sidransky Ph.D Self Board Member 000 0000
Dazhong Lv Ascentage Pharma Board Member 000 0000
Eric Zhao Oriza Holdings Board Member 000 0000
Lawrence Tian Ph.D YuanMing Capital Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Ascentage Pharma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ascentage Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ascentage Pharma‘s full profile, request access.

Request a free trial

Ascentage Pharma Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 01-Feb-2016 00000 0000 Media and Information Services (B2B)
To view Ascentage Pharma’s complete investments history, request access »